Evaluation of the Antiproliferative Effect of Extract from Equisetum arvense L. on Hepatocellular Carcinoma SNU-449 Cells

Year 2025, Volume: 4 Issue: 1, 53 - 61

Ayşe Burçin Uyumlu

https://doi.org/10.71133/anatphar.1641474

Abstract

Equisetum arvense L. (Horsetail) extract (HTE) has been used traditionally in the treatment of various ailments. However, its potential as an anticancer agent, particularly in hepatocellular carcinoma (HCC), is still not well understood. The objective of this study is to investigate the anticancer potential of HTE in the SNU449 HCC cells. To assess the antiproliferative and migratory properties of HTE on HCC, a cell viability was analyzed at 24 and 48nd hours using seven different concentrations of HTE (ranging from 7.81 to 500 ppm). The lowest concentration that effectively affected cell viability was determined, and subsequent experiments were carried out using this dose at the 24-hour mark. The MTT, colony formation, wound healing, and Western blotting assays to measure CASP-3 and Cleaved CASP-3 expressions were also included in the analysis. The MTT assay identified 326 ppm as the minimum effective dose at the 24-hour time point. Colony formation assays showed a notable difference between treated and untreated cells, with a surviving fraction of 46.9% in HTE-treated cells. The wound healing assay indicated that HTE-treated cells exhibited a 43.4% wound closure rate after 24 hours. Western blot analysis revealed the normalized volume ratios for Caspase-3 were 53222328 in the treated cells, and 7948593 in the control, while for Cleaved Caspase-3, the ratios were 707454 in treated cells and 596409 in control cells. The results suggest that HTE has antiproliferative and migratory properties on SNU-449 HCC cells. Further investigations are required to understand the underlying mechanisms of these effects.

Keywords

Equisetum arvense L., Horsetail, Antiproliferative Effects, SNU-449 Cell Line

Project Number

Proje yok

References

• Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249.
• Singh AK, Kumar R, Pandey AK. Hepatocellular carcinoma: causes, mechanism of progression and biomarkers. Curr Chem Genom Transl Med. 2018;12:9–26.
• McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of hepatocellular carcinoma. Hepatology. 2021;73:4–13.
• Ganesan P, Kulik LM. Hepatocellular carcinoma: new developments. Clin Liver Dis. 2023;27:85–102.
• Yu LX, et al. Role of nonresolving inflammation in hepatocellular carcinoma development and progression. npj Precision Oncology. 2018;2:6.
• Rayginia TP, Kizhakkeveettil CK, Shifana SC, Pellissery MJ, Abhishek A, John Anto R. Phytochemicals as potential lead molecules against hepatocellular carcinoma. Curr Med Chem. 2024;31(32):5199–5221.
• Dormousoglou M, Efthimiou I, Antonopoulou M, et al. Investigation of the genotoxic, antigenotoxic, and antioxidant profile of different extracts from Equisetum arvense L. Antioxidants. 2022;11(8):1393.
• Al-Fahad D, Al-Harbi B, Abbas Y, Al-Yaseen F. A comparative study to visualize PtdIns(4,5)P2 and PtdIns(3,4,5)P3 in MDA-MB-231 breast cancer cell line. Rep Biochem Mol Biol. 2022;10(4):518-526.
• Sandhu NS, Kaur S, Chopra D. Pharmacognostic evaluation of Equisetum arvense Linn. Int J PharmTech Res. 2010;2:1460–1464.
• Choopani A, Fazilati M, Latifi AM, et al. An efficient method for extraction and enrichment of γ-linolenic acid (GLA) from Spirulina. Letters in Applied NanoBioScience. 2022;11(1):3166–3174.
• Asgarpanah J, Roohi E. Phytochemistry and pharmacological properties of Equisetum arvense L. J Med Plants Res. 2012;6(21):3689-3693.
• Al-Snafi AE. The pharmacology of Equisetum arvense—A review. IOSR J Pharm. 2017;7(2):31-42.
• Stajner D, Popović BM, Canadanović-Brunet J, Anackov G. Exploring Equisetum arvense L., Equisetum ramosissimum L., and Equisetum telmateia L. as sources of natural antioxidants. Phytother Res. 2009;23(4):546-550.
• Sola-Rabada A, Rinck J, Belton DJ, Powell AK, Perry CC. Isolation of a wide range of minerals from a thermally treated plant: Equisetum arvense, a mare's tail. JBIC J Biol Inorg Chem. 2016;21(1):101–112.
• Cetojevic-Simin DD, Canadanovic-Brunet JM, Bogdanovic GM, et al. Antioxidative and antiproliferative activities of different horsetail (Equisetum arvense L.) extracts. J Med Food. 2010;13(2):452-459.
• Carneiro DM, Jardim TV, Luciana Araújo YC, et al. Equisetum arvense: new evidence supporting medical use in daily clinic. Pharmacogn Rev. 2021;13:50-58.
• Şahinler Ş. Equisetum arvense L., in: Novel Drug Targets With Traditional Herbal Medicines. Springer, Cham. 2022:249-262.
• Van Meerloo J, Kaspers GJ, Cloos J. Cell sensitivity assays: the MTT assay. Cancer cell culture: methods and protocols. 2011: 237-245.
• Franken NA, Rodermond HM, Stap J, Haveman J, Van Bree C. Clonogenic assay of cells in vitro. Nature protocols. 2006; 1(5), 2315-2319.
• Wang B, Lan T, Xiao H, Chen ZH, Wei C, Chen LF, et al. The expression profiles and prognostic values of HSP70s in hepatocellular carcinoma. Cancer cell international. 2021;21(1), 286.
• Oh H, Kim DH, Cho JH, Kim YC. Hepatoprotective and free radical scavenging activities of phenolic petrosins and flavonoids isolated from Equisetum arvense. J Ethnopharmacol. 2004;95(2-3):421-424.
• Al Mohammed HI, Paray BA, Rather IA. Anticancer activity of EA1 extracted from Equisetum arvense. Pak J Pharm Sci. 2017;30(5):1947-1950.
• Yamamoto Y, Inoue T, Hamako J. Crude proteins extracted from Equisetum arvense L. increase the viability of cancer cells in vivo. Seibutsu Shiryo Bunseki. 2004;27(5):409-412.
• Saleem O. Screening of medical plants on skin cancer cell lines A375 and B16 using cell viability assay. PhD thesis, University of East London. 2019.
• Heitham T. Effect of crude extracts of vegetative and callus parts of Melia azedarach on cancer and normal cell (in vitro). MSc thesis, College of Biotechnology, University of Alnahrain, Iraq. 2007.